What have we really learned from ‘LIBERATE’ trial?

Received 24 November 2009; received in revised form 15 February 2010; accepted 22 February 2010. published online 08 March 2010.

Abstract

LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate.

Keywords: Breast cancer, Tibolone, Recurrence, LIBERATE trial, Menopausal symptoms

a 1st Department of Ob/Gyn, Athens University Medical School, Athens, Greece

b NICHD, NIH, Bethesda, MD, USA

Corresponding author at: 1st dept of Ob/Gyn, Athens University Medical School, 80 Vas. Sophias Avenue, 115 28 Athens, Greece. Tel.: +30 6974441697.

PII: S0378-5122(10)00079-4

doi:10.1016/j.maturitas.2010.02.012

18 of 20